Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics
Ari Breiner, Lorne Zinman, Pierre R. Bourque
Abstract
KEY POINTS Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition that results in progressive paralysis of limb and bulbar muscles, with an average life expectancy of 3–5 years after diagnosis. Until 2017, riluzole was the only approved medication for patients with ALS,
Topics & Concepts
Amyotrophic lateral sclerosisRiluzoleEdaravoneMedicinePhysical medicine and rehabilitationParalysisLife expectancySurgeryDiseaseAnesthesiaPathologyPopulationEnvironmental healthAmyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders ResearchParkinson's Disease Mechanisms and Treatments